Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Peptide Vaccine With Resiquimod as an Immune Modulator for Patients With Resected Melanoma: A Pilot Study

NCT01748747 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT01748747
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01748747 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Peptide Vaccine With Resiquimod as an Immune Modulator for Patients With Resected Melanoma: A Pilot Study
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2012
Completion date
March 30, 2017
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent melanoma, stage iia melanoma, stage iib melanoma, stage iic melanoma, stage iiia melanoma, stage iiib melanoma, stage iiic melanoma, stage iv melanoma